Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP001541

Drug Information
NameValdecoxib    
SynonymsSpectrum3_001001; KBio2_002227; InChI=1/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20; NCGC00095129-02; Pfizer brand of valdecoxib; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; Spectrum2_000508; COX; KBio2_007363; NCGC00095129-01; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-; Valdecoxib (USAN/INN); KBio3_001941; SPECTRUM1504302; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- (9CI); Valdecoxib; HMS1922J21; UNM-0000305814; AC-120; SC-65872; MLS001424105; ZINC00006694; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide; KBio2_004795; CPD000466327; NCGC00095129-03; BRD-K12994359-001-02-8; SC 65872; UNII-2919279Q3W; HMS2051P07; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; HSDB 7302; YM-974; C406224; ND-0214; Valdyn; 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; D02709; CHEBI:41662; 181695-72-7; MLS000759433; SAM001246603; BSPBio_002721; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; Spectrum5_001476; MLS001165699; MLS001195631; DB07576; Spectrum4_001129; p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Valdecoxib [USAN]; DB00580; KBioGR_001617; CHEMBL865; Bextra; CID119607; 2aw1; MolPort-000-883-874; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; KBioSS_002227; SPBio_000435; SMR000466327; Spectrum_001747; AKOS000280920; Kudeq; C16H14N2O3S; LS-173713; AC1L3P42    
IndicationOsteoarthritis and rheumatoid arthritisApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassAnti-inflammatory Agents    
CAS NumberCAS 181695-72-7
PubChem Compound IDCID 119607.    
PubChem Substance IDSID 587378.    
SuperDrug ATC IDM01AH03;    
SuperDrug CAS ID181695727;    
TargetCyclooxygenase 2Inhibitor[1]
Ref 1Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and safety. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543